SGS Expands Biomarker Services with Validation of a New Multiplex Pro-Inflammatory Panel for Testing Clinical Samples
SGS Life Science Services has announced that its laboratory in Poitiers, France, has successfully completed a full analytical validation of the novel Meso Scale Discovery (MSD) V-PLEX 10-plex Proinflammatory Panel I, for use with human plasma samples. The validation included measurement of accuracy, recovery, dilutional linearity, and stability, using a set of in-house, as well as the manufacturer’s surrogate validation quality controls.
This new service offering, complementing SGS’s existing biomarker portfolio, will enable the laboratory to generate more information by quantification of multiple biomarkers, and as 10 assays can be conducted in parallel, save on the volume of clinical samples required, while reducing turnaround time and cost for customers.
The Panel measures 10 cytokines that are important in inflammatory response and immune system regulation, as well as numerous other biological processes. These assays can detect biomarkers produced in a variety of tissues and body fluids, where over- or under-expression may indicate a shift in biological equilibrium. It also includes assays for many of the Th1/Th2 pathway biomarkers and measures biomarkers that are implicated in various disorders, including rheumatoid arthritis, Alzheimer’s disease, asthma, atherosclerosis, allergies, systemic lupus erythematosus, obesity, cancer, depression, multiple sclerosis, diabetes, psoriasis and Crohn’s disease.
“We have deep understanding and expertise in the use of multiplex platforms as one of the routine bioanalytical procedures for clinical testing,” commented Dr Rabia Hidi, SGS Life Science Services Director of Biomarkers & Biopharmaceutical Testing. She added: “We can produce robust data and fully validate multiplexing methods to offer both quality of data and cost convenience, while using the minimum sample volumes. Where SGS differentiates itself in this space, is that our multiplexing methods can be fully validated and used in decision making studies.”
Related News
-
News Pharmaceutical Supply Chain People Moves
The latest appointments, promotions, and structural changes across the pharmaceutical supply chain.
-
News Merck KGaA to buy US biotech SpringWorks for US$3.9 billion
The German multinational pharmaceutical company Merck KGaA have signed a deal to buy US biotech company SpringWorks Therapeutics at an equity value of US$3.9 billion in a move to add rare cancer therapeutics to their pipelines.
-
News Cassava Sciences halts Alzheimer's drug trial after limited progress
Cassava Sciences have drawn a close to their investigations and development of the drug simufilam, which they intended to be used for the treatment of Alzheimer’s disease.
-
News US FDA adds haemodialysis bloodlines to devices shortage list
On March 14, 2025, the US FDA published an open letter to healthcare providers citing continuing supply disruptions of haemodialysis bloodlines, an essential component of dialysis machines.
-
News Vertex Pharmaceuticals stock jumps as FDA approves non-opioid painkiller
UK-based Vertex Pharmaceuticals saw their stock shares soar as the US FDA signed off on the non-opioid painkiller Journavx, also known as suzetrigine, for patients with moderate to severe acute pain, caused by surgery, accidents, or injuries.
-
News Lessons from CPHI Milan 2024: Sunny Intervals for Pharma Manufacturing?
As the 2024 CPHI conference wrapped up in Milan, we caught up with L.E.K. Consulting – a global strategy consulting firm with deep expertise in pharma manufacturing – to discuss evolving market perspectives and business outlook. -
News US BIOSECURE Act passed by US House of Representatives
The controversial act, which has already impacted several foreign companies operating in the US, was passed by the House of Representatives on September 9, 2024. It is now headed for the US Senate before it can be signed into law by President Joe Biden... -
News Drug prices agreed upon as part of the US Inflation Reduction Act
The Inflation Reduction Act brought into constitution by the Biden administation in 2022, which proposed a drug price negotiation between the government and pharmaceutical companies, has reached it's first agreement.